Company Overview and News

Fiscal Reforms: An Imperative For Sustained Growth

2016-10-23 colombotelegraph
Sustained growth is normally viewed from two different angles today. One is from the point of environment and depletion of non-renewable resources. The other is from the point of a country’s ability to sustain a high economic growth based on technological advancement, infrastructure and quality of human capital. Economic growth involves the delivery of an ever increasing high volume of material goods and services to people.

CB’s power to bailout troubled finance companies challenged

Former Deputy Governor Wijewardena says notion of taxpayers’ money being used to pay defrauded depositors flawed

Chanuka Ratwatta Granted Bail

2016-10-21 colombotelegraph
Chanuka Ratwatte and four others were granted bail today by Colombo Fort Magistrate. They were each released on a cash bail of Rs. 300,000 and two sureties of Rs. 2 million per suspect.

CIFL share trading halted, share price drops by 20%

Trading of shares from Central Investments & Finance Limited (CIFL) was halted at the Colombo Stock Exchange (CSE) this morning (19 October). According to the CSE, this step had been taken pending a clarification from the company.

Central Bank resolves four insolvent financial institutions to protect depositors and promote the financial system stability

As announced to the public on 10.10.2016, the Monetary Board at its meeting held on 14.10.2016 considered resolution issues pertaining to a number of non-bank financial institutions in the context of relevant legal provisions in the interest of protecting the public trust in the financial system. Accordingly, the Monetary Board approved a resolution mechanism for repayment of depositors of three finance companies and legitimate investors in government securities-linked investments in Entrust Securities PLC.

Sri Lanka Central Bank resolves four insolvent institutions

2016-10-19 lankabusinessonline
Oct 19, 2016 (LBO) – Sri Lanka’s Monetary Board says it has approved repayments to depositors and investors in four insolvent financial institutions.

Whistle-Blowing On Perpetual Treasuries: Embarrassing But Vindication Of CB’s Supervisory Staff

2016-10-09 colombotelegraph
The market last week was livid with a leaked on-site examination report, claimed to have been prepared by Central Bank’s primary dealer supervision staff, on the controversial primary dealer, Perpetual Treasuries.

Chanuka Ratwatte Further Remanded Over Multi-Billion Financial Fraud

2016-10-07 colombotelegraph
Chanuka Ratwatte and four other board members of Entrust Securities were ordered to be further remanded till October 21 by the Colombo Fort Magistrate.

Chanuka Ratwatte And Entrust Board Members File Bail Applications; Magistrate Orders Them To Be Remanded

2016-09-30 colombotelegraph
The Colombo Fort Magistrate today further remanded Chanuka Ratwatte and four other board members of Entrust Securities till October 7 for misappropriating funds amounting to Rs. 4.2 billion which belonged to over 350 investors. Meanwhile, the lawyers of Ratwatta and the four other board members have also filed written bail applications.

Chanuka Ratwatte And Four Others Arrested For Rs. 12 Billion Financial Fraud

2016-09-14 colombotelegraph
Chanuka Ratwatte, along with four others who were arrested today by the Financial Crimes Investigation Division (FCID) over alleged financial fraud charges committed by them at Entrust Securities PLC, were remanded till September 28.

Sri Lanka’s CB to take-over Entrust Securities

2016-01-04 lankabusinessonline
Jan 04, 2015 (LBO) - Sri Lanka's Central Bank is to take-over Entrust Securities Plc, primary dealer in government securities if the company fails to submit a viable restructuring plan today, Gover...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...